Date | Topic | Presenter |
09/21/2020 | CRISPR and Coronavirus | |
01/15/2021 | Developing Clinical Trials of Cell and Gene Therapy | |
01/29/2021 | Cell Therapies in Trauma and Critical Care Medicine: Translational Barriers and Future Directions | |
06/23/2021 | Protecting cells from immune destruction is the key to unlocking the potential regenerative medicine | Sonja Schrepfer, MD, PhD |
12/06/2021 | A Breakthrough in aTTP treatment now recommended by the ISTH guidelines | Jay Raval, MD |
03/04/2022 | Adoptive Cell Therapy with on-site produced Tumor Infiltrated Lymphocytes or CD19 CAR T cells – Updated results of 500 enrolled patients | |
| 07/22/2022 | History of the Treg Program at UCSF | Qizhi Tang, PhD |
| 04/26/2023 | Engineering the Hematopoietic System by Genome Editing | Michael Porteus, MD, PhD |
| 06/02/2023 | Cellular Therapies for Neurological Injuries: How will we know it is working? | Charles S. Cox, Jr., MD |
| 07/25/2023 | cGMP manufacturing of KIND T cells to treat diffuse midline glioma | Jonathan Esensten, MD, PhD |
| 10/18/2023 | OMX - A Novel Oxygen Delivery Biotherapeutic for Treatment of Hemorrhagic Shock | Emin Maltepe, MD, PhD |
| 02/20/2024 | Programming Immunotherapies with CRISPR | Alex Marson, MD, PhD |
| 04/10/2024 | Engineering Erythropoiesis | Kyle Cromer, PhD |
| 09/12/2024 | Persistent HIV Infection Of Human B Cells For Evaluation Of Broadly Neutralizing Antibodies (bNAB) | Girish N. Vyas, PhD, FRCPath |
| 12/04/2024 | The Hidden Components: Extracellular Vesicles and Mitochondrial DNA in Blood Products | Philip J. Norris, MD |
